Status:
COMPLETED
Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers
Lead Sponsor:
Taisho Pharmaceutical Co., Ltd.
Conditions:
Healthy
Eligibility:
All Genders
21-54 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to healthy adult subjects.
Detailed Description
Evaluation of safety and pharmacokinetics
Eligibility Criteria
Inclusion
- Males or females of non-childbearing capacity aged 21 to 55 years inclusive at screening.
- Body mass index in the range of 18 to 30 kg/m2 and body weight\>45 kg.
- Healthy as determined by the investigator on the basis of screening evaluation.
Exclusion
- Use of prescription or nonprescription drugs
- Any condition possibly affecting drug absorption
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00756743
Start Date
September 1 2008
End Date
January 1 2009
Last Update
March 19 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Singapore, Singapore, 188770